2-4 ich quality guidances : an overview
DESCRIPTION
2-4 ICH Quality Guidances : an overview. PQP Assessment Training January 18-21, 2012 Satish Mallya. January 18-21, 2012. ICH Topics. Stability - Q1A – Q1F Analytical Validation – Q2 Impurities – Q3A - Q3C (Q3D – concept paper) Pharmacopoeias – Q4A - Q4B (and annexes) - PowerPoint PPT PresentationTRANSCRIPT
Satish Mallya January 20-22, 20101 |
2-4 ICH Quality Guidances:an overview
2-4 ICH Quality Guidances:an overview
PQP Assessment Training
January 18-21, 2012
Satish Mallya
January 18-21, 2012
Satish Mallya January 20-22, 20102 |
ICH TopicsICH Topics
Stability - Q1A – Q1F
Analytical Validation – Q2
Impurities – Q3A - Q3C (Q3D – concept paper)
Pharmacopoeias – Q4A - Q4B (and annexes)
Quality of Biotechnological Products – Q5A – Q5E
Specifications – Q6A – Q6B
Good Manufacturing Practice – Q7
Pharmaceutical Development – Q8
Quality Risk Management - Q9
Pharmaceutical Quality System – Q10
Development and Manufacturing of Drug Substances – Q11
January 18-21, 2012
Satish Mallya January 20-22, 20103 |
FocusFocus
Stability - Q1A, B, C, D, E & F
Validation of Analytical Methods – Q2(R1)
Impurities – Q3A, B & C
Specifications – Q6A (Chemical Substances) & Q6B & Q6B (Biotechnology/Biological Products) (Biotechnology/Biological Products)
January 18-21, 2012
Satish Mallya January 20-22, 20104 |
StabilityStability
Q1A(R2) Stability Testing of New Drug Substances and Products
Q1B Photostability Testing of New Drug Substances and Products
Q1C Stability Testing for New Dosage Forms
Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products
Q1E Evaluation of Stability Data
Q1F Stability Data Package for Registration Applications in Climatic Zones III & IV (withdrawn – June 2006)
January 18-21, 2012
Satish Mallya January 20-22, 20105 |
Q1A(R2) STABILITY TESTING OF
NEW DRUG SUBSTANCES AND PRODUCTS
Q1A(R2) STABILITY TESTING OF
NEW DRUG SUBSTANCES AND PRODUCTS
Drug SubstanceDrug ProductStress testingPhotostability testing
Selection of batchesSelection of batches
Container closure systemContainer closure system
SpecificationSpecification
Testing frequencyTesting frequency
Storage conditionsStorage conditions
Stability commitmentStability commitment
EvaluationEvaluation
Statements/LabelingStatements/Labeling
January 18-21, 2012
Satish Mallya January 20-22, 20106 |
Stress Testing/Photostability Stress Testing/Photostability
Drug Substance Drug Product
One primary batch
Effect of temperatures (in 10°C increments (e.g., 50°C, 60°C, etc.) above that for accelerated testing)
Effect of humidity (e.g., > 75%RH)
One primary batch
As in ICH Q1B:
January 18-21, 2012
Satish Mallya January 20-22, 20107 |
Selection of BatchesSelection of Batches
Drug Substance Drug Product
Data on at least three primary batches of minimum pilot scale manufactured by the same synthetic route as used for production batches.
Data on at least three primary batches of the drug product – two pilot and third one can be smaller - same formulation and packaged in the same container closure system as proposed for marketing.
The manufacturing process used for primary batches should simulate that to be applied to production batches
Where possible, use different batches of the drug substance.
Should be performed on each individual strength and container size of the drug product unless bracketing or matrixing is applied.
January 18-21, 2012
Satish Mallya January 20-22, 20108 |
Container Closure SystemContainer Closure System
Drug SubstanceDrug Product
Studies to be conducted on the API packaged in a container closure system that is identical to or simulates the proposed commercial packaging
Studies to be carried out in container closure system identical to commercial packaging; studies carried out in other packaging materials can be used as supporting information
January 18-21, 2012
Satish Mallya January 20-22, 20109 |
SpecificationSpecification
Drug Substance Drug Product Studies to include attributes
susceptible to change during storage and which can influence quality, safety and efficacy: - Physical- Chemical- Microbiological
Studies to include attributes susceptible to change during storage and which can influence quality, safety and efficacy:- Physical- chemical,- microbiological,- preservative content- functionality tests (e.g. with
delivery systems)
Validated analytical methods to be employed
Validated analytical methods to be employed
June 2010January 18-21, 2012
Satish Mallya January 20-22, 201010 |
Testing Frequency Testing Frequency
Drug Substance Drug ProductFor API with proposed re-test period/shelf-life of at least 12 months: Every 3 months over first year, every 6 months over next 12 months and annually thereafter.
For FPP with proposed re-test period/shelf-life of at least 12 months: Every 3 months over first year, every 6 months over next 12 months and annually thereafter.
Accelerated condition: Minimum of 3 time points, including initial and final time points (e.g. 0, 3 & 6 months)
Accelerated condition: Minimum of 3 time points, including initial and final time points (e.g. 0, 3 & 6 months)
Intermediate condition (due to significant change under accelerated condition): study design should include 4 time points (e.g. 0, 6, 9 and 12 months
Intermediate condition (due to significant change under accelerated condition): study design should include 4 time points (e.g. 0, 6, 9 and 12 months)
Matrixing or Bracketing may be applied
June 2010January 18-21, 2012
Satish Mallya January 20-22, 201011 |
Storage Conditions Storage Conditions
General Case Drug Substance Drug Product
StudyStorage Conditions
Minimum period covered by data at submission
StudyStorage Conditions
Minimum period covered by data at submission
Long term25 C⁰ +2 C/ 60%⁰+5%RH or30 C⁰ +2 C /65% ⁰+5%RH
12 monthsLong term25 C⁰ +2 C /60%⁰+5%RH or30 C⁰ +2 C /65% ⁰+5%RH
12 months
Intermediate30 C⁰ +2 C /65% ⁰+5%RH
6 monthsIntermediate30 C⁰ +2 C /65% ⁰+5%RH
6 months
Accelerated40 C⁰ +2 C /75% ⁰+5%RH
6 monthsAccelerated40 C⁰ +2 C /75% ⁰+5%RH
6 months
June 2010January 18-21, 2012
Satish Mallya January 20-22, 201012 |
Storage ConditionsStorage Conditions
Storage in refrigerator Drug Substance Drug Product
StudyStorage Conditions
Minimum period covered by data at submission
StudyStorage Conditions
Minimum period covered by data at submission
Long term5 C ⁰ + 3 C⁰12monthsLong term5 C ⁰ + 3 C⁰12months
Accelerated25 C ⁰ + 2 C / 60% ⁰+ 5% RH
6 months Accelerated25 C ⁰ + 2 C / ⁰60% + 5% RH
6 months
June 2010January 18-21, 2012
Satish Mallya January 20-22, 201013 |
Storage Conditions Storage Conditions
Storage in freezer
Storage below - 20 C : Case by case basis⁰
Drug Substance Drug Product
StudyStorage Conditions
Minimum period covered by data at submission
StudyStorage Conditions
Minimum period covered by data at submission
Long term
- 20 C ⁰ + 5 C⁰12monthsLong term
- 20 C ⁰ + 5 C⁰12months
June 2010January 18-21, 2012
Satish Mallya January 20-22, 201014 |
Storage Conditions – Drug ProductStorage Conditions – Drug Product
Semi-permeable containers :
StudyStorage ConditionsMinimum period covered by data at submission
Long term25 C⁰ +2 C/40%⁰ +5% RH or30 C⁰ +2 C/35%⁰ +5% RH
12 months
Intermediate30 C⁰ +2 C/65%⁰ +5% RH6 months
Accelerated40 C⁰ +2 C/⁰ NMT 25% RH6 months
June 2010January 18-21, 2012
Satish Mallya January 20-22, 201015 |
Significant ChangeSignificant Change
Drug SubstanceDrug Product
Defined as failure to meet specifications
->5% change in assay from the initial results
-Any degradation product exceeding its acceptance criterion
-Failure to meet acceptance criteria for appearance, physical attributes and functionality tests
-Failure to meet acceptance criteria for pH
-Failure to meet acceptance criteria for dissolution of 12 dosage units
January 18-21, 2012
Satish Mallya January 20-22, 201016 |
EvaluationEvaluation
Drug Substance Drug ProductStatistical analysis not necessary if data exhibits little or no degradation and variability
Statistical analysis not necessary if data exhibits little or no degradation and variability
Limited extrapolation of real time data permitted with justification
Limited extrapolation of real time data permitted with justification
June 2010January 18-21, 2012
Satish Mallya January 20-22, 201017 |
Q1B PHOTOSTABILITY TESTING OF
NEW DRUG SUBSTANCES AND PRODUCTS
Q1B PHOTOSTABILITY TESTING OF
NEW DRUG SUBSTANCES AND PRODUCTS
Provides 2 options for sources of light:– artificial daylight fluorescent lamp combining visible and ultraviolet
(UV) outputs, xenon, or metal halide lamp– sample should be exposed to both the cool white fluorescent and near
ultraviolet lamp
Test on API first – if not photosensitive then no further testing is required
If API is photosensitive then testing to be continued on (as appropriate):
– Tests on the exposed drug product outside of the immediate pack – Tests on the drug product in the immediate pack – Tests on the drug product in the marketing pack
Where appropriate, impact of light during manufacturing
January 18-21, 2012
Satish Mallya January 20-22, 201018 |
Q1C Annex to Q1A (R2)
Q1C Annex to Q1A (R2)
Additional guidance on line extensions
Reduced requirements at time of filing: 6 months accelerated and 6 months long term
January 18-21, 2012
Satish Mallya January 20-22, 201019 |
Q1D - BracketingQ1D - Bracketing
January 18-21, 2012
Satish Mallya January 20-22, 201020 |
Q1D - MatrixingQ1D - Matrixing
January 18-21, 2012
Satish Mallya January 20-22, 201021 |
Q1D - MatrixingQ1D - Matrixing
January 18-21, 2012
Satish Mallya January 20-22, 201022 |
Q1E
EVALUATION OF STABILITY DATA
Q1E
EVALUATION OF STABILITY DATA
Provides recommendations for: (at RT, Refrigerated and Freezer storages)
– treating stability data – Extending re-test period or shelf-life beyond period covered by
long-term data– Statistical approaches to analysis of stability data
Progression: – Start with data under accelerated condition – Then assess data under intermediate condition, if appropriate– Finally evaluate trends and variability of the long-term data
January 18-21, 2012
Satish Mallya January 20-22, 201023 |
OutcomesOutcomes
When there is no significant change under accelerated conditions (RT)
Long-term and accelerated data showing little or no change over time and little or no variability
Retest period or shelf life can be up to twice, but NMT 12 months beyond the period covered by long-term data
Long-term or accelerated data showing change over time and/or variability
Data not amenable to statistical analysis, but relevant supporting data provided: Retest period or shelf life can be up to 1.5 times, but NMT 6 months beyond the period covered by long-term data
If a statistical analysis is performed: Retest period or shelf life of up to twice, but not more than 12 months beyond the
period covered by long-term data
January 18-21, 2012
Satish Mallya January 20-22, 201024 |
OutcomesOutcomes
When there is significant change under accelerated conditions (RT) but no significant change at intermediate condition:
Data not amenable to statistical analysis:
Retest period or shelf life can be up to 3 months beyond the period covered by long-term data if backed by relevant documentation
If statistical analysis is performed:
Retest period or shelf life can be up to 1.5 times, but NMT 6 months beyond the period covered by long-term data when backed by statistical analysis and relevant supporting data
January 18-21, 2012
Satish Mallya January 20-22, 201025 |
Q2(R1) VALIDATION OF ANALYTICAL PROCEDURES
Q2(R1) VALIDATION OF ANALYTICAL PROCEDURES
Defines validation characteristics:– Accuracy – Precision
• Repeatability • Intermediate Precision
– Specificity – Detection Limit – Quantitation Limit – Linearity – Range
Robustness to be considered at appropriate stage of development of the analytical method
System suitability test parameters to be established for a particular procedure depending on the type of procedure being validated - Pharmacopoeias to be consulted for additional information
January 18-21, 2012
Satish Mallya January 20-22, 201026 |
VALIDATION CHARACTERISTICSVALIDATION CHARACTERISTICS
Validation characteristics
ID Impurities
Quant. limit
Assay
Accuracy
Precision
Repeatibility
Int.Precision
Specificity
LOD
LOQ
Linearity
Range
-
-
-
+
-
-
-
-
+ -
+ -
+ -
+ +
- +
+ -
+ -
+ -
+
+
+
+
-
-
+
+
January 18-21, 2012
Satish Mallya January 20-22, 201027 |
Q3 Impurities
Q3 Impurities
Impurities in New Drug Substances Q3A(R2): Defines thresholds for reporting, identification and qualification of impurities in DS
Impurities in New Drug Products Q3B(R2): Defines thresholds for reporting, identification and qualification of impurities in DP
Guideline for Residual Solvents Q3C (R5): Classifies residual solvents by risk assessment:
– Class 1 solvents: solvents to be avoided– Class 2 solvents: solvents to be limited– Class 3 solvents: solvents with low toxic potential
Guideline for Metal Impurities Q3D (Concept paper – July 2009)
January 18-21, 2012
Satish Mallya January 20-22, 201028 |
Q3A(R2) CLASSIFICATION OF IMPURITIES
Q3A(R2) CLASSIFICATION OF IMPURITIES
Organic Impurities– Starting materials– By-products– Intermediates– Degradation products– Reagents, ligands, catalysts
Inorganic Impurities– Reagents, ligands, catalysts– Heavy metals or other residual metals– Inorganic salts– Other materials (e.g., filter aids, charcoal)
Residual Solvents
January 18-21, 2012
Satish Mallya January 20-22, 201029 |
Q3A(R2) Definitions
Q3A(R2) Definitions
Qualification: The process of acquiring and evaluating data that establishes the biological safety of an individual impurity or a given impurity profile at the level(s) specified.
Reporting Threshold: A limit above (>) which an impurity should be reported.
Specified Impurity: An impurity that is individually listed and limited with a specific acceptance criterion in the new drug substance specification. A specified impurity can be either identified or unidentified.
Unidentified Impurity: An impurity for which a structural characterisation has not been achieved and that is defined solely by qualitative analytical properties (e.g., chromatographic retention time)
Unspecified impurity: An impurity that is limited by a general acceptance criterion, but not individually listed with its own specific acceptance criterion, in the new drug substance specification
January 18-21, 2012
Satish Mallya January 20-22, 201030 |
Q3A(R2)Q3A(R2)
January 18-21, 2012
Satish Mallya January 20-22, 201031 |
Q3A(R2)Q3A(R2)
January 18-21, 2012
Satish Mallya January 20-22, 201032 |
Q3B(R2)Q3B(R2)
January 18-21, 2012
Satish Mallya January 20-22, 201033 |
Q3B(R2)Q3B(R2)
January 18-21, 2012
Satish Mallya January 20-22, 201034 |
Q3C(R5)Q3C(R5)
Provides 2 options for describing limits of Class 2 Solvents
Option 1: As per the table provided - calculated using TDI of 10 g and the calculation -
– Concentration (ppm) = 1000 x Permitted Daily Exposure (PDE)/ Dose– PDE is given in terms of mg/day and dose is given in g/day.
If TDI is more than 10 g use option 2
SolventPDE (mg/day)Concentration limit (ppm)
Acetonitrile
Chlorobenzene
4.1
3.6
410
360
January 18-21, 2012
Satish Mallya January 20-22, 201035 |
Example for Option 2Example for Option 2
Option 2: It is not considered necessary for each component of the drug product to comply with the limits given in Option 1. The PDE in terms of mg/day can be used with the known maximum daily dose and equation (Concentration (ppm) = 1000 x PDE/ Dose) to determine the concentration of residual solvent allowed in drug product
Example: PDE of acetonitrile is 4.1mg/day
Component Amount in formulation Acetonitrile content Daily exposure
Drug substance 0.3 g 800 ppm 0.24 mg
Excipient 1 0.9 g 400 ppm 0.36 mg
Excipient 2 3.8 g 800 ppm 3.04 mg
Drug Product 5.0 g 728 ppm 3.64 mg
The sum of the amounts of solvent per day should be less than that given by the PDE.
January 18-21, 2012
Satish Mallya January 20-22, 201036 |
Q6AQ6A
Addresses aspects such as:– Periodic or skip testing– Release vs shelf-life criteria– In-process tests– Design and development considerations– Limited data available at filing– Parametric release– Alternative procedures– Pharmacopoeial tests and acceptance criteria– Evolving technologies– Impact of drug substance on drug product specifications– Reference standard
January 18-21, 2012
Satish Mallya January 20-22, 201037 |
Q6A Decision Trees
Q6A Decision Trees
#1 – Establishing acceptance criteria for specified impurity In DS
#2 – Establishing acceptance criteria for degradation product in DP
#3 – Establishing acceptance criteria for PSD in DS
#4 – Investigating need to set acceptance criteria for polymorphism in DS and DP
#5 – Establishing ID, Assay and enantiomeric impurity procedures for chiral DS and chiral DS in DP
#6 – Microbiological Quality Attributes of DS and Excipients
#7 – Setting acceptance criteria for DP dissolution
#8 – Microbiological Quality Attributes of non sterile DP
January 18-21, 2012
Satish Mallya January 20-22, 201038 |
Periodic or Skip TestingPeriodic or Skip Testing
Should be justified.
May be applied to certain tests only (e.g. residual solvents and microbiological test for solid oral products)
Recommend that it should be applied post approval
Batch to batch retesting to be restored in the event of failure
January 18-21, 2012
Satish Mallya January 20-22, 201039 |
Design and Development ConsiderationsDesign and Development Considerations
It may be possible to propose excluding or replacing certain tests based on experience and data accumulated:
– microbiological testing for drug substances and solid dosage forms which have been shown during development not to support microbial viability or growth (Decision Trees #6 and #8)
– extractables from product containers where it has been reproducibly shown that either no extractables are found in the drug product or the levels meet accepted standards for safety
January 18-21 2012January 18-21, 2012
Satish Mallya January 20-22, 201040 |
Design and Development ConsiderationsDesign and Development Considerations
– particle size testing may be performed as an in-process test, or may be performed as a release test, depending on its relevance to product performance
– dissolution testing for immediate release solid oral drug products made from highly water soluble drug substances may be replaced by disintegration testing, if these products have been demonstrated during development to have consistently rapid drug release characteristics (Decision Tree #7) (only accepted in exceptional circumstances and all conditions must be met including substantial development data)
January 18-21, 2012
Satish Mallya January 20-22, 201041 | January 18-21, 2012